On Wednesday—for only the second time—the Food and Drug Administration approved a cutting-edge therapy that genetically modifies a patient’s blood cells in order to attack cancer. This time the therapy, known as CAR T-cell therapy, is designed to treat aggressive non-Hodgkin lymphoma.
from Gizmodo http://ift.tt/2yzYXO2
Author Name
Author Description!
Get Free Email Updates to your Inbox!
Post a Comment